PARIS (Agefi-Dow Jones)–Valneva announced on Monday that it is in discussions with a potential partner for funding to develop a second-generation vaccine against Covid-19. “These discussions could continue for several months and may not result in an agreement,” the biotech company added.
Valneva had previously indicated that it would invest in the development of a second generation vaccine against Covid-19 only if it received the necessary funding or a funding commitment during the third quarter of 2022.
In parallel, Valneva said it is continuing discussions with various governments and regulatory authorities around the world, with the aim of deploying the remaining stocks in international markets within the next 12 months.
The biotech company also plans to “report additional clinical data by the end of the year, including heterologous recall data, which could potentially support the sell-off of these stocks.”
-Vincent Alsuar, Agefi-Dow Jones; +33 (0)1 41 27 47 39; [email protected] ed: VLV
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
September 26, 2022 01:18 ET (05:18 GMT)